Phosphatidylzidovudine

Drug Profile

Phosphatidylzidovudine

Latest Information Update: 30 Jun 1999

Price : $50

At a glance

  • Originator Vical
  • Developer Gilead Sciences; Vical
  • Class Antivirals; Nucleosides; Phospholipids
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 30 Jun 1999 Discontinued-Preclinical for HIV infections treatment in USA (Unknown route)
  • 21 Jul 1998 No-Development-Reported for HIV infections treatment in USA (Unknown route)
  • 27 Mar 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top